Comparison of Pharmacokinetics of CS-866 (Olmesartan Medoxomil), an Angiotensin II Receptor Antagonist, in Elderly and Non-elderly Subjects
|
Accession number;03A0865486
|
| Title;Comparison of Pharmacokinetics of CS-866 (Olmesartan Medoxomil), an Angiotensin II Receptor Antagonist, in Elderly and Non-elderly Subjects |
| Author;
TANAKA TAKANORI
(Aiseikai Osakikurinikku)
URAE RYUJI
(Aiseikai Osakikurinikku)
HISAOKA MASAFUMI
(Sankyo Co., Ltd., JPN)
SHIGA HIROSHI
(Sankyo Co., Ltd., JPN)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.19;NO.11;PAGE.1297-1306(2003)
|
| Figure&Table&Reference;FIG.2, TBL.7, REF.7 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;CS-866 (Olmesartan medoxomil) is an orally active angiotensin II receptor antagonist and an antihypertensive agent. It is converted to an active metabolite, RNH-6270, after oral administration. Pharmacokinetics of CS-866 in healthy elderly and non-elderly subjects were compared after a single dose in this trial. Ten mg of CS-866 was orally administrated to 6 elderly subjects and 6 non-elderly subjects. Point estimates and 95% confidence intervals of the AUC0-24 ratio (elderly vs. non-elderly) were 1.03 and 0.76-1.41, respectively, and those values of Cmax were 0.94 and 0.68-1.31, respectively. Point estimates of elderly versus non-elderly subjects were near 1, but 95 % confidence intervals exceeded the range from 0.8 to 1.25 due to variability. Since there were only small differences in the mean values of AUC0-24 and Cmax between two age groups, it was considered that there is no clinically significant difference in pharmacokinetics. Concerning safety, no clinically significant abnormalities were confirmed in both age groups. (author abst.) |
|
|
|
Related Articles;
|
|
